Curadoria · Saúde

Biotech

Por InspectStocksPublished 14 de out. de 202619 companies0 follower

Drug developers with approved medicines, built mainly on biologic and genetic science.

Agrupadas com a ajuda de um modelo de IA e revisadas pelos nossos editores. A linha abaixo de cada empresa diz por que ela está aqui.

Download image

Cartões Níveis

Os preços das ações são o fechamento de 11 de nov. de 2026, do feed da bolsa IEX.

Grade mix

A 8B 4C 5D 1F 1

Revenue growing

18 of 19

Free cash flow growing

13 of 18

Median price move, 1 year

+29,0%

Sort by

VRTXVERTEX PHARMACEUTICALS INC / MA
BiotechnologyMarket cap US$ 138,7BP/E 35,22
US$ 547,02+26,0%1Y
Since added +12,7%
B+
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Forte
Getting better
Melhorando
Revenue
US$ 13B+10,5%
Profit
US$ 4B+8,2%
Free cash flow
US$ 3,2B-4,0%
Discuss
Why it is here: Develops and sells cystic fibrosis and other medicines
REGNREGENERON PHARMACEUTICALS, INC.
BiotechnologyMarket cap US$ 101,3BP/E 21,18
US$ 959,45+41,5%1Y
Since added +27,4%
C+
Crescimento e caixa
Crescendo
Business trend
Acelerando
Business quality
Forte
Getting better
Melhorando
Revenue
US$ 16,9B+18,6%
Profit
US$ 4,8B+5,2%
Free cash flow
US$ 3,8B-9,4%
Discuss
Why it is here: Develops and sells antibody therapies for eye, allergy and cancer conditions
GILDGILEAD SCIENCES, INC.
Drug manufacturers generalMarket cap US$ 210,5BSem P/L (prejuízo operacional)
US$ 169,73+40,9%1Y
Since added +14,8%
A
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Mista
Getting better
Melhorando
Revenue
US$ 31B+6,5%
Profit
-US$ 3,9B-147,6%
Free cash flow
US$ 13,8B+50,4%
Discuss
Why it is here: Sells medicines for HIV, liver disease and cancer
ALNYALNYLAM PHARMACEUTICALS, INC.
BiotechnologyMarket cap US$ 21,4BP/E 68,58
US$ 159,80-64,7%1Y
Since added -28,6%
B+
Crescimento e caixa
Crescendo com força
Business trend
Desacelerando
Business quality
Forte
Getting better
Melhorando
Revenue
US$ 3,7B+65,2%
Profit
US$ 2,6B+2.136,9%
Free cash flow
US$ 465,4M+1.192,7%
Discuss
Why it is here: Develops and sells RNAi therapeutics
BIIBBIOGEN INC.
Drug manufacturers generalMarket cap US$ 37,5BP/E 109,22
US$ 253,39+56,9%1Y
Since added +10,7%
A
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Sólida
Getting better
Misto
Revenue
US$ 10,3B+2,3%
Profit
US$ 347,5M-78,4%
Free cash flow
US$ 2,1B-10,1%
Discuss
Why it is here: Develops and sells therapies for neurological diseases
INSMINSMED INC
BiotechnologyMarket cap US$ 26,5BSem P/L (prejuízo operacional)
US$ 120,64-37,9%1Y
Since added +24,7%
C-
Crescimento e caixa
Crescendo
Business trend
Estável
Business quality
Fraca
Getting better
Misto
Revenue
US$ 1,5B+240,0%
Profit
-US$ 605,6M+48,8%
Free cash flow
-US$ 627,6M+30,7%
Discuss
Why it is here: Develops and sells therapies for rare lung diseases
UTHRUnited Therapeutics Corporation
Drug manufacturers specialty and genericMarket cap US$ 25,4BP/E 22,48
US$ 595,58+29,0%1Y
Since added +9,6%
C+
Crescimento e caixa
Crescendo com força
Business trend
Desacelerando
Business quality
Forte
Getting better
Melhorando com força
Revenue
US$ 3,2B+1,9%
Profit
US$ 1,2B-3,2%
Free cash flow
US$ 867,2M-22,7%
Discuss
Why it is here: Sells therapies for pulmonary arterial hypertension
NBIXNEUROCRINE BIOSCIENCES, INC.
Drug manufacturers specialty and genericMarket cap US$ 17,6BP/E 25,87
US$ 174,35+18,7%1Y
Since added +29,0%
A+
Crescimento e caixa
Crescendo com força
Business trend
Acelerando
Business quality
Forte
Getting better
Melhorando
Revenue
US$ 3,7B+38,0%
Profit
US$ 702,5M+64,1%
Free cash flow
US$ 1B+75,3%
Discuss
Why it is here: Develops and sells therapies for neurological and endocrine disorders
MRNAModerna, Inc.
BiotechnologyMarket cap US$ 100,6BSem P/L (prejuízo operacional)
US$ 248,70+831,1%1Y
Since added +15,0%
C-
Crescimento e caixa
Crescendo
Business trend
Acelerando
Business quality
Fraca
Getting better
Piorando
Revenue
US$ 2,5B+13,1%
Profit
-US$ 2,8B+10,5%
Free cash flow
-US$ 2B+25,7%
Discuss
Why it is here: Develops mRNA vaccines and therapies
BMRNBioMarin Pharmaceutical Inc
BiotechnologyMarket cap US$ 11,3BNo P/E
US$ 58,32+5,4%1Y
Since added +7,3%
B
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Mista
Getting better
Melhorando
Revenue
US$ 3,7B+18,1%
Profit
-US$ 19,1M-103,7%
Free cash flow
US$ 557,9M-33,0%
Discuss
Why it is here: Develops and sells therapies for rare genetic diseases
INCYINCYTE CORPORATION
BiotechnologyMarket cap US$ 24,9BP/E 65,01
US$ 122,23+12,9%1Y
Since added +12,6%
C
Lucro e valor patrimonial
Crescendo
Business quality
Mista
Getting better
Melhorando com força
Revenue
US$ 6B+24,9%
Profit
US$ 403,4M-66,1%
Free cash flow
US$ 892,1MNo comparable year
Discuss
Why it is here: Develops and sells oncology and inflammation therapies
EXELEXELIXIS, INC.
BiotechnologyMarket cap US$ 17,3BP/E 21,17
US$ 70,71+62,2%1Y
Since added +18,8%
A+
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Forte
Getting better
Melhorando
Revenue
US$ 2,5B+9,1%
Profit
US$ 885,1M+30,6%
Free cash flow
US$ 1,2B+48,9%
Discuss
Why it is here: Develops and sells cancer therapies
BNTXBioNTech SE
BiotechnologyMarket cap US$ 22BSem P/L (prejuízo operacional)
US$ 87,64-21,5%1Y
Since added -1,5%
F
Crescimento e caixa
Misto
Business trend
Encolhendo
Business quality
Mista
Getting better
Melhorando
Revenue
US$ 2,7B-23,2%
Profit
-US$ 1,6B-157,7%
Free cash flow
US$ 314M+456,5%
Discuss
Why it is here: Develops mRNA vaccines and cancer therapies
JAZZJazz Pharmaceuticals plc
BiotechnologyMarket cap US$ 15,9BP/E 80,84
US$ 248,18+81,5%1Y
Since added +18,0%
A
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Mista
Getting better
Melhorando
Revenue
US$ 4,7B+13,5%
Profit
US$ 206M+155,9%
Free cash flow
US$ 1,6B+21,3%
Discuss
Why it is here: Develops and sells neuroscience and oncology therapies
HALOHALOZYME THERAPEUTICS, INC.
BiotechnologyMarket cap US$ 11,6BP/E 25,36
US$ 101,69+44,0%1Y
Since added -7,2%
A+
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Forte
Getting better
Melhorando
Revenue
US$ 1,8B+45,0%
Profit
US$ 485,4M-18,5%
Free cash flow
US$ 885,9M+47,1%
Discuss
Why it is here: Licenses drug delivery technology and sells enzyme-based therapies
ASNDAscendis Pharma A/S
BiotechnologyMarket cap US$ 16,1BSem P/L (prejuízo operacional)
US$ 259,10+30,1%1Y
Since added +16,0%
D
Lucro e valor patrimonial
Misto
Business quality
Mista
Getting better
Melhorando
Revenue
US$ 1,2B+113,4%
Profit
-US$ 254,8M+39,7%
Free cash flow
-US$ 293,2M+54,2%
Discuss
Why it is here: Develops and sells endocrinology rare disease therapies
BBIOBridgeBio Pharma, Inc.
BiotechnologyMarket cap US$ 15,5BSem P/L (prejuízo operacional)
US$ 79,53+20,1%1Y
Since added +25,6%
B
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Mista
Getting better
Piorando
Revenue
US$ 945,5M+167,3%
Profit
-US$ 573,8M+28,6%
Free cash flow
-US$ 369,8M+36,9%
Discuss
Why it is here: Develops therapies for genetic diseases
CORTCORCEPT THERAPEUTICS INC
BiotechnologyMarket cap US$ 8,2BP/E 58,68
US$ 74,52-4,9%1Y
Since added -36,7%
A+
Crescimento e caixa
Crescendo com força
Business trend
Acelerando
Business quality
Forte
Getting better
Misto
Revenue
US$ 963,6M+30,0%
Profit
US$ 162,3M+52,9%
Free cash flow
US$ 194,6M+19,2%
Discuss
Why it is here: Develops and sells cortisol-modulating therapies
KRYSKrystal Biotech, Inc.
BiotechnologyMarket cap US$ 9,2BP/E 41,90
US$ 308,82+52,1%1Y
Since added -3,9%
A+
Crescimento e caixa
Crescendo com força
Business trend
Estável
Business quality
Forte
Getting better
Melhorando
Revenue
US$ 470M+26,0%
Profit
US$ 225,2M+13,2%
Free cash flow
US$ 310,1M+87,3%
Discuss
Why it is here: Develops and sells topical gene therapies for rare diseases

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.